AU2004252419B2 - Method and carrier complexes for delivering molecules to cells - Google Patents

Method and carrier complexes for delivering molecules to cells Download PDF

Info

Publication number
AU2004252419B2
AU2004252419B2 AU2004252419A AU2004252419A AU2004252419B2 AU 2004252419 B2 AU2004252419 B2 AU 2004252419B2 AU 2004252419 A AU2004252419 A AU 2004252419A AU 2004252419 A AU2004252419 A AU 2004252419A AU 2004252419 B2 AU2004252419 B2 AU 2004252419B2
Authority
AU
Australia
Prior art keywords
dmt
dalda
arg
phe
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004252419A
Other languages
English (en)
Other versions
AU2004252419A1 (en
Inventor
Alex V. Birk
Hugh D. Robertson
Hazel Szeto
Kesheng Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of AU2004252419A1 publication Critical patent/AU2004252419A1/en
Application granted granted Critical
Publication of AU2004252419B2 publication Critical patent/AU2004252419B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
AU2004252419A 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells Expired AU2004252419B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46751603P 2003-05-01 2003-05-01
US60/467,516 2003-05-01
PCT/US2004/013772 WO2005001023A2 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells

Publications (2)

Publication Number Publication Date
AU2004252419A1 AU2004252419A1 (en) 2005-01-06
AU2004252419B2 true AU2004252419B2 (en) 2010-02-18

Family

ID=33551404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004252419A Expired AU2004252419B2 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells

Country Status (17)

Country Link
US (6) US7704954B2 (enExample)
EP (7) EP2604286B1 (enExample)
JP (6) JP4879020B2 (enExample)
KR (1) KR101161823B1 (enExample)
CN (2) CN101214380A (enExample)
AU (1) AU2004252419B2 (enExample)
BR (1) BRPI0409911A (enExample)
CA (1) CA2524258C (enExample)
DK (4) DK2604621T3 (enExample)
ES (3) ES2520815T3 (enExample)
MX (1) MXPA05011773A (enExample)
NZ (1) NZ543410A (enExample)
PL (2) PL2604286T3 (enExample)
PT (2) PT2604286E (enExample)
SI (1) SI2604285T1 (enExample)
WO (1) WO2005001023A2 (enExample)
ZA (1) ZA200509229B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
WO2005072295A2 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP3659618A1 (en) 2003-02-04 2020-06-03 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
SI2604285T1 (sl) 2003-05-01 2014-12-31 Cornell Research Foundation, Inc. Postopek in nosilni kompleksi za dovajanje molekul celicam
US7534819B2 (en) * 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
KR101426070B1 (ko) 2005-09-16 2014-08-01 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
JP2010509181A (ja) * 2005-11-04 2010-03-25 フォーヒューマンテック・カンパニー・リミテッド 融合ポリペプチドを細胞へ輸送する方法
CN101490080A (zh) * 2006-07-24 2009-07-22 为人技术株式会社 用于缓解和治疗缺血性病症的药物组合物及其输送方法
KR20090045940A (ko) * 2006-08-29 2009-05-08 포휴먼텍(주) 세포자멸사의 억제를 위한 약학 조성물, 및 이를 전달하는 방법
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
ES2458870T3 (es) 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
BRPI0918948A2 (pt) * 2008-09-22 2015-12-15 Aileron Therapeutics Inc macrociclos peptidomiméticos
CA2743177A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
CN102573881A (zh) * 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
EP3067061A1 (en) * 2009-08-12 2016-09-14 Cornell University Methods for preventing or treating metabolic syndrome
LT3708178T (lt) 2009-08-24 2023-12-27 Stealth Biotherapeutics Inc. Peptidas, skirtas naudoti makulos degeneracijos prevencijai arba gydymui
CA2776581C (en) * 2009-10-05 2020-12-15 Cornell University Methods for the prevention or treatment of heart failure
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
WO2011139992A1 (en) * 2010-05-03 2011-11-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
GB201018125D0 (en) * 2010-10-26 2010-12-08 Marealis As Peptide
EP2688579A4 (en) * 2011-03-24 2015-10-21 Univ Cornell CATIONIC AROMATIC PEPTIDES AND USES THEREOF
JP2014518213A (ja) * 2011-06-14 2014-07-28 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族カチオン性ペプチド及びその使用
JP6025311B2 (ja) 2011-08-01 2016-11-16 キヤノン株式会社 眼科診断支援装置および方法
AU2012315586B2 (en) 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
CN104114181B (zh) * 2011-10-17 2017-06-09 康奈尔大学 芳香族阳离子肽及其用途
CA2852468A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
WO2013086020A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
WO2013155334A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
WO2014174517A1 (en) 2013-04-25 2014-10-30 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
EP3114136A4 (en) * 2014-03-03 2017-11-01 Stealth BioTherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
WO2015183995A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EP3502132A1 (en) * 2014-05-28 2019-06-26 Stealth BioTherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
WO2015197723A1 (en) 2014-06-25 2015-12-30 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
HUE055687T2 (hu) * 2014-06-30 2021-12-28 Flamma Spa Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016209261A1 (en) * 2015-06-26 2016-12-29 Stealth Biotherapeutics Corp Therapeutic compositions including gramicidin s peptidyl conjugates or imidazole-substituted fatty acids, variants thereof, and uses thereof
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
CA3039906A1 (en) 2015-10-21 2017-04-27 The Regents Of The University Of Michigan Detection and treatment of caries and microcavities with nanoparticles
US20200308220A1 (en) * 2015-11-30 2020-10-01 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3049099A1 (en) 2016-11-16 2018-05-24 Luca Science Inc. Method for producing myocardial stem cell for use in treatment and/or prevention of cardiac arrest
WO2018124162A1 (ja) * 2016-12-28 2018-07-05 中外製薬株式会社 化合物の膜透過性を改善するための自己乳化型製剤
CN107230021B (zh) * 2017-06-08 2020-05-26 桂林理工大学 筛选供水管网泄漏区域的方法
CA3102155A1 (en) * 2018-06-29 2020-01-02 Glykos Biomedical Oy Conjugates
EP4081192A2 (en) 2019-12-27 2022-11-02 LUCA Science Inc. Isolated mitochondria with smaller size and lipid membrane-based vesicles encapsulating isolated mitochondria
WO2021216499A1 (en) * 2020-04-23 2021-10-28 North Carolina State University Cell-penetrating peptide-microrna conjugates for intracellular cell delivery
JP2023541403A (ja) 2020-09-09 2023-10-02 ソーシャル・プロフィット・ネットワーク ビオチンをミトコンドリアに送達するための方法及び組成物
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029796A1 (en) * 2000-07-18 2004-02-12 Hazel Szeto Medicinal uses of mu-opioid receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500053A (enExample) * 1978-01-16 1980-01-31
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5714327A (en) 1990-07-19 1998-02-03 Kreatech Diagnostics Platinum-containing compounds, methods for their preparation and applications thereof
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
EP1037911A4 (en) * 1997-12-10 2003-07-23 Univ Washington ANTI-PATHOGEN SYSTEM AND METHOD FOR USE THEREOF
US6268398B1 (en) * 1998-04-24 2001-07-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
EP1226115A4 (en) * 1999-10-04 2006-03-15 Univ New Jersey Med NEW CARBAMATES AND UREES
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
GB0026924D0 (en) * 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
MXPA03007358A (es) * 2001-02-16 2004-12-13 Cellgate Inc Transportadores que contienen porciones de arginina separadas.
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
EP3659618A1 (en) * 2003-02-04 2020-06-03 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
WO2005072295A2 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
SI2604285T1 (sl) * 2003-05-01 2014-12-31 Cornell Research Foundation, Inc. Postopek in nosilni kompleksi za dovajanje molekul celicam
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
KR101426070B1 (ko) 2005-09-16 2014-08-01 코넬 리서치 화운데이션,인크. Ｃｄ36 발현을 감소시키는 방법
US20070259377A1 (en) 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
ES2458870T3 (es) 2008-02-07 2014-05-07 Cornell University Procedimientos para prevenir o tratar la resistencia a la insulina
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
WO2020005756A1 (en) 2018-06-29 2020-01-02 Reald Spark, Llc Stabilization for privacy display

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040029796A1 (en) * 2000-07-18 2004-02-12 Hazel Szeto Medicinal uses of mu-opioid receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bickel et al "Synthesis and Bioactivity of Monobiotinylated DALDA: Au- Specific Opioid Peptide Designed for Targeted Brain Delivery." Journal of Pharmacological and Experimental Therapeutics. Vol. 268, No.2, pp. 791-796. *

Also Published As

Publication number Publication date
MXPA05011773A (es) 2006-02-17
US11845807B2 (en) 2023-12-19
JP2016130246A (ja) 2016-07-21
EP2604286B1 (en) 2014-08-27
EP2604621B1 (en) 2015-10-21
JP6698756B2 (ja) 2020-05-27
JP2014221846A (ja) 2014-11-27
JP2018158951A (ja) 2018-10-11
PL2604285T3 (pl) 2015-02-27
JP2020105184A (ja) 2020-07-09
ES2520816T3 (es) 2014-11-11
WO2005001023A2 (en) 2005-01-06
EP1625149A4 (en) 2010-10-06
HK1231424A1 (en) 2017-12-22
HK1186406A1 (en) 2014-03-14
SI2604285T1 (sl) 2014-12-31
US9315586B2 (en) 2016-04-19
CA2524258C (en) 2012-08-07
DK2604621T3 (en) 2016-02-01
US20170035899A1 (en) 2017-02-09
US20100204448A1 (en) 2010-08-12
EP2604285B1 (en) 2014-08-27
EP3167935B1 (en) 2018-07-18
EP2604287A3 (en) 2014-04-16
EP3167935A1 (en) 2017-05-17
US20050158373A1 (en) 2005-07-21
BRPI0409911A (pt) 2006-04-25
EP3381515A1 (en) 2018-10-03
AU2004252419A1 (en) 2005-01-06
JP2007503461A (ja) 2007-02-22
KR101161823B1 (ko) 2012-07-03
JP6395749B2 (ja) 2018-09-26
NZ543410A (en) 2008-07-31
DK2604286T3 (en) 2014-12-08
JP4879020B2 (ja) 2012-02-15
JP5995930B2 (ja) 2016-09-21
DK2604285T3 (en) 2014-12-01
US20220372172A1 (en) 2022-11-24
US8148322B2 (en) 2012-04-03
PT2604285E (pt) 2014-11-12
US10584182B2 (en) 2020-03-10
CN101214380A (zh) 2008-07-09
HK1253888A1 (en) 2019-07-05
US7704954B2 (en) 2010-04-27
EP1625149B1 (en) 2016-02-17
EP1625149A2 (en) 2006-02-15
HK1186407A1 (en) 2014-03-14
EP2604286A1 (en) 2013-06-19
PT2604286E (pt) 2014-11-28
US11180574B2 (en) 2021-11-23
CN1780851A (zh) 2006-05-31
ES2520815T3 (es) 2014-11-11
DK1625149T3 (en) 2016-05-30
PL2604286T3 (pl) 2015-03-31
WO2005001023A3 (en) 2005-04-28
EP2604285A1 (en) 2013-06-19
EP2604287A2 (en) 2013-06-19
JP5650040B2 (ja) 2015-01-07
ES2694574T3 (es) 2018-12-21
US20200299415A1 (en) 2020-09-24
US20130085259A1 (en) 2013-04-04
KR20060008950A (ko) 2006-01-27
EP3381515B1 (en) 2020-07-08
HK1186482A1 (en) 2014-03-14
EP2604621A1 (en) 2013-06-19
ZA200509229B (en) 2007-03-28
EP2604287B1 (en) 2016-12-07
CN100506841C (zh) 2009-07-01
JP2011168603A (ja) 2011-09-01
CA2524258A1 (en) 2005-01-06
HK1089450A1 (zh) 2006-12-01

Similar Documents

Publication Publication Date Title
US11845807B2 (en) Method and carrier complexes for delivering molecules to cells
HK1253888B (en) Carrier complexes for delivering molecules to cells
HK1186405A (en) Method and carrier complexes for delivering molecules to cells
HK1121683A (en) Method and carrier complexes for delivering molecules to cells
HK1089450B (en) Method and carrier complexes for delivering molecules to cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired